Neurotrophic Growth Factors
Product description
The present Competitive Intelligence Report about neurotrophic growth factors provides a competitor evaluation in the field of molecules such as proteins, peptides, antibodies, DNA, RNA, cells and small molecules directly or indirectly stimulating growth of nervous system tissue as of December 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Early clinical trials with classical neurotrophic growth factor proteins such as NGF, BDNF, CNTF have failed for various reasons including safety, efficacy and convenience of administration as well as right definition of the clinical indication. Today quite a number of clinical and preclinical studies are evaluating new approaches of neuroprotection or -regeneration in various neurological disorders including neuropathies, stroke, spinal cord injuries, Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, multiple sclerosis or Huntington’s disease. Among the approaches are the classical growth factors engineered to pass the blood-brain barrier or to be expressed by locally delivered cells. Small molecules are in development as neurotrophic agents with favourable drug-like and pharmacological properties. Antibodies are also used to block pathways inhibitory for axonal regeneration or neurite outgrowth, thereby inducing functional recovery. More than 16 molecules are in clinical evaluation, further two approaching entry into humans and more than 16 in preclinical stages.
The report includes a compilation of currently active projects in research and development of proteins, peptides, antibodies, DNA, RNA, cells and small molecules directly or indirectly stimulating growth and repair of nervous system tissue. In addition, the report lists company-specific R&D pipelines of neurotrophic growth factors. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Index
Growth Factors for Use in
- Neuropathies
- Stroke
- Parkinson’s disease
- Spinal Cord Injury
- Amyotrophic Lateral Sclerosis (ALS) / Lou Gehrig’s disease
- Alzheimer’s disease
- Multiple sclerosis
- Huntington’s disease
- Ophthalmic diseases
- Various
- Corporate Neurotrophic Growth Factor R&D Pipelines
- About La Merie
About Competitor Analysis Series The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. Competitor analysis reports can be purchased as individual products or obtained by subscribing to R&D Pipeline News. R&D Pipeline News is published weekly 50-times a year and each issue contains at least two competitor evaluations. Individual products from the Competitor Analysis Series and R&D Pipeline News are independently elaborated by analysts of La Merie Business Intelligence and distributed by PipelineReview.com.
|
